整理 | GLP1减重宝典内容团队丹麦制药公司诺和诺德(Novo Nordisk),作为减重药物Wegovy的制造商,近日在美国面临一宗集体诉讼。投资者指控公司对财务前景过于乐观,未如实披露肥胖症药物市场面临的激烈竞争风险,从而误导了市场。该诉讼于上周五在美国新泽西州联邦法院提起,正值诺和诺德市值在一天内大幅缩水700亿美元之后。投资者称,公司对2025年营收和利润的下调暴露出其增长预期存在严重...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.